DSM lodges patent infringement law suit in China; seeks monetary damages

07-Aug-2018 - Last updated on 07-Aug-2018 at 03:49 GMT

The company is seeking an injunction against Anhui Tiger, the competitor in question.

DSM is pursuing a patent infringement law suit in China against a competitor for alleged misappropriation of intellectual property related to the production of a key ingredient of Biotin, also known as vitamin B7 or vitamin H.

The firm said in a brief statement that DSM IP Assets BV and two related operating group companies, DSM Vitamins (Shanghai) Ltd and DSM Vitamins Trading (Shanghai) Ltd, served a suit against Anhui Tiger in China for patent infringement.

DSM is seeking an injunction preventing Anhui Tiger from using an innovative, patented process for the 'environmentally friendly' manufacture of a key ingredient in Biotin. In addition, DSM is seeking monetary damages resulting from Anhui Tiger's alleged infringement.

Senior VP Thomas Beck said: "Our business has always been focused on bringing new and innovative processes, advanced products and nutritional solutions to our customers in the animal and human micronutrient market. Developing and protecting intellectual property is a key component of our strategy to support our significant investments in that market.

"We are confident in the value and strength of our patent portfolio, and we will defend our intellectual property across the world when necessary. The present litigation underlines DSM's seriousness and confidence in enforcing its IP rights."

Biotin is commonly used in pregnancy supplements, and supplements designed to improve hair, skin and nail health.